Articles by Reflector - Pharmaceutical Executive

ADVERTISEMENT

Articles by Reflector

Reflector


Reflector is Pharm Exec Europe's man inside the EU.

Articles
Eruptions on the Drug-Pricing Horizon in Europe
October 1, 2014

An escalating political debate over pharma pricing and reimbursement nears the boiling point.

Eruptions on Europe's Drug-Pricing Horizon
September 22, 2014

The EU may have a new monitoring scheme for Iceland's volatile geology, but it should also heed the volcano that could blow apart its assumptions on drug pricing and reimbursement, says Reflector.

Peril, Not Progress on Transatlantic Trade Deal
September 1, 2014

Pharma hopes for a deal are fading as the once-hot TTIP talks seem to be on the fizzle in Europe.

TTIP: From Hot Tip to Oblivion?
August 18, 2014

The Transatlantic Trade and Investment Partnership (TTIP) was the hot tip for a 2014 success story. But as summer slides away, the latest read-out of progress suggests that rather than remaining a hot tip, TTIP is now risking oblivion...

EFPIA's 'Integrated Strategy' in Europe: Out of the Frying Pan, Into the Fire?
August 1, 2014

Industry's grand vision for reshaping the life sciences in Europe may ultimately prove to be a lost cause.

Europe Gears Up to Attack Counterfeit Medicines—But Only Some of Them
July 1, 2014

Cross-sector partnership seeks support for a pan-European system to keep fake drugs out, but obstacles are many.

Hopes High as EU Heads Into Leadership Change
June 1, 2014

Rare allies—innovator and generic pharmas—are calling for policy integration in Europe. But ideology and newfound scepticism on the merits of drugs in healthcare could complicate the effort.

Rebuilding European Pharma's Competitive Agenda
May 19, 2014

Because of the tougher conditions they face and shifts in ownership and corporate strategy, EFPIA and EGA have started to work together much more closely.

European Clinical Trials: The Die Is Cast
April 15, 2014

Politicians and health campaigners are celebrating the final agreement of the EU's new clinical trials rules. But the European drug industry is not so euphoric, writes Reflector.

ADVERTISEMENT

Click here